VivoSim gets $5M milestone from Eli Lilly and projects 500%+ revenue growth in FY2027

VivoSim Labs, Inc. said it received a $5 million milestone payment from Eli Lilly, linking the cash infusion to ongoing collaboration related to VivoSim’s 3D human cellular model platform used in preclinical research. The payment was disclosed in an announcement picked up by Yahoo Finance on July 15, as investors focused on how the smaller company’s revenue trajectory could change if additional development milestones are met.

In the same update, VivoSim also provided forward-looking guidance, saying it expects revenue growth of 500% or more in fiscal 2027. Revenue growth of that magnitude implies a step-change in topline driven by scaling programs, ramping customer adoption, or moving additional work through later stages of development and validation, although the company did not detail which of those factors would be decisive.

VivoSim is a provider of next-generation New Approach Methodologies, commonly referred to as NAM 3D human cellular models. NAM is a broad term in drug development for alternative approaches intended to reduce reliance on certain traditional testing methods by using more human-relevant systems. VivoSim’s models are designed to support preclinical decision-making, where sponsors want better human translation and faster iteration than conventional approaches.

Eli Lilly, VivoSim’s partner in the collaboration described by the announcement, is a major drugmaker that uses a mix of in-house and external platforms to support discovery and early development. For a small supplier like VivoSim, milestone payments can matter because they often correspond to technical progress, the acceptance of deliverables, or the passage of defined development checkpoints.

Still, the Yahoo Finance write-up did not lay out further specifics that investors typically seek in these arrangements. It did not disclose the milestone’s contractual trigger in plain terms, the overall value or duration of the collaboration, whether the relationship includes additional milestone payments beyond the $5 million, or how much of the projected 500%+ revenue growth is tied to this Eli Lilly relationship versus other customers.

That gap matters because guidance can be sensitive to timing. For example, a large year-over-year jump can result from a single large program milestone shifting into the fiscal period, or it can reflect a broader pipeline of contracts maturing. Without the supporting breakdown, analysts and investors will have limited visibility into what must happen operationally for the fiscal 2027 target to be credible.

What to watch next is whether VivoSim follows up with additional disclosure around the collaboration’s structure and deliverables, and whether it reports progress markers that support the revenue ramp implied by its guidance. Investors will likely look for subsequent updates that quantify remaining near-term milestones, customer adoption of its model platform, and any evidence that Eli Lilly-related work is scaling beyond the initial payment.

As of the information in the Yahoo Finance-referenced announcement, the most concrete figures were the $5 million milestone receipt and the expectation of 500%+ revenue growth in fiscal 2027. The company did not provide, in that item, enough detail to determine the degree of dependence on Eli Lilly, or the specific drivers behind the growth estimate.